196 related articles for article (PubMed ID: 9108082)
1. "Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue.
Tarleton RL; Zhang L; Downs MO
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3932-7. PubMed ID: 9108082
[TBL] [Abstract][Full Text] [Related]
2. Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine.
Rosas-Jorquera CE; Sardinha LR; Pretel FD; Bombeiro AL; D'Império Lima MR; Alvarez JM
Clin Vaccine Immunol; 2013 Feb; 20(2):248-54. PubMed ID: 23254299
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD4 abrogates rejection and reestablishes long-term tolerance to syngeneic newborn hearts grafted in mice chronically infected with Trypanosoma cruzi.
dos Santos RR; Rossi MA; Laus JL; Silva JS; Savino W; Mengel J
J Exp Med; 1992 Jan; 175(1):29-39. PubMed ID: 1730921
[TBL] [Abstract][Full Text] [Related]
4. Trypanosoma cruzi: cross-reactive anti-heart autoantibodies produced during infection in mice.
McCormick TS; Rowland EC
Exp Parasitol; 1989 Nov; 69(4):393-401. PubMed ID: 2509236
[TBL] [Abstract][Full Text] [Related]
5. Bloodstream Trypanosoma cruzi parasites from mice simultaneously express antigens that are markers of acute and chronic human Chagas disease.
Leguizamon MS; Campetella OE; Reyes MB; Ibañez CF; Basombrio MA; Rincon J; Orn A; Frasch AC
Parasitology; 1991 Jun; 102 Pt 3():379-85. PubMed ID: 1907729
[TBL] [Abstract][Full Text] [Related]
6. Trypanosoma cruzi antigen-specific antibody response in immunized mice during acute and chronic infection.
Mikhail KS; Rowland EC
J Parasitol; 1990 Oct; 76(5):690-7. PubMed ID: 2120413
[TBL] [Abstract][Full Text] [Related]
7. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
Bhatia V; Garg NJ
Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
Gupta S; Garg NJ
PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
[TBL] [Abstract][Full Text] [Related]
9. Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection.
Duthie MS; Kahn M; Zakayan A; White M; Kahn SJ
Clin Vaccine Immunol; 2007 Aug; 14(8):1005-12. PubMed ID: 17538117
[TBL] [Abstract][Full Text] [Related]
10. [Immune response to Trypanosoma cruzi. An approach to the pathogenesis of Chagas' disease].
Braun M; de Titto E
Acta Physiol Pharmacol Latinoam; 1985; 35(1):1-47. PubMed ID: 2932884
[TBL] [Abstract][Full Text] [Related]
11. A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.
Zrein M; Granjon E; Gueyffier L; Caillaudeau J; Liehl P; Pottel H; Cardoso CS; Oliveira CDL; de Oliveira LC; Lee TH; Ferreira AM; Ribeiro ALP; Busch MP; Sabino EC
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006226. PubMed ID: 29425201
[TBL] [Abstract][Full Text] [Related]
12. Trypanosoma cruzi-induced molecular mimicry and Chagas' disease.
Gironès N; Cuervo H; Fresno M
Curr Top Microbiol Immunol; 2005; 296():89-123. PubMed ID: 16323421
[TBL] [Abstract][Full Text] [Related]
13. Autoimmunity in Chagas' disease: specific inhibition of reactivity of CD4+ T cells against myosin in mice chronically infected with Trypanosoma cruzi.
Rizzo LV; Cunha-Neto E; Teixeira AR
Infect Immun; 1989 Sep; 57(9):2640-4. PubMed ID: 2474498
[TBL] [Abstract][Full Text] [Related]
14. Trypanosoma cruzi calreticulin: a possible role in Chagas' disease autoimmunity.
Ribeiro CH; López NC; Ramírez GA; Valck CE; Molina MC; Aguilar L; Rodríguez M; Maldonado I; Martínez R; González C; Troncoso R; Lavandero S; Gingras AR; Schwaeble W; Ferreira A
Mol Immunol; 2009 Mar; 46(6):1092-9. PubMed ID: 19108895
[TBL] [Abstract][Full Text] [Related]
15. Isotype determination of anti-Trypanosoma cruzi antibody in murine Chagas' disease.
Rowland EC; Mikhail KS; McCormick TS
J Parasitol; 1992 Jun; 78(3):557-61. PubMed ID: 1375959
[TBL] [Abstract][Full Text] [Related]
16. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
Front Immunol; 2020; 11():565142. PubMed ID: 33162979
[TBL] [Abstract][Full Text] [Related]
17. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
[TBL] [Abstract][Full Text] [Related]
18. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
[TBL] [Abstract][Full Text] [Related]
19. The influence of T cell subsets on Trypanosoma cruzi multiplication in different organs.
Russo M; Starobinas N; Marcondes MC; Minoprio P; Honteyberie-Joskowicz M
Immunol Lett; 1996 Mar; 49(3):163-8. PubMed ID: 8739311
[TBL] [Abstract][Full Text] [Related]
20. Effects of IFN-γ coding plasmid supplementation in the immune response and protection elicited by Trypanosoma cruzi attenuated parasites.
Pérez Brandán C; Mesías AC; Parodi C; Cimino RO; Pérez Brandán C; Diosque P; Basombrío MÁ
BMC Infect Dis; 2017 Nov; 17(1):732. PubMed ID: 29178839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
